https://www.pharmaradar360.com/article/campylobacter-infection-annual-data-02c1dd6f758d5376Pharma Surgeen2026-07-08T16:20:55.000ZCampylobacter infection: annual datahttps://www.pharmaradar360.com/article/why-the-government-must-urgently-raise-the-nice-cost-effectiveness-threshold-1b734b641caf26ebPharma Surgeen2026-07-08T16:16:12.000ZWhy the government must urgently raise the NICE cost-effectiveness thresholdhttps://www.pharmaradar360.com/article/understanding-nhs-medicines-spending-in-england-8db3f6e3ab405423Pharma Surgeen2026-07-08T16:12:08.000ZUnderstanding NHS medicines spending in Englandhttps://www.pharmaradar360.com/article/abpi-response-to-life-sciences-competitiveness-indicators-8b0806f016033b51Pharma Surgeen2026-07-08T16:10:13.000ZABPI response to Life Sciences Competitiveness Indicatorshttps://www.pharmaradar360.com/article/health-protection-in-children-and-young-people-s-settings-including-education-cca215b8fd3fb49bPharma Surgeen2026-07-08T15:46:52.000ZHealth protection in children and young people's settings, including educationhttps://www.pharmaradar360.com/article/dhsc-public-appointments-2026-to-2027-92f3e9c4047ba1dcPharma Surgeen2026-07-08T15:10:06.000ZDHSC public appointments: 2026 to 2027https://www.pharmaradar360.com/article/sana-biotech-heads-to-easd-with-diabetes-cell-therapy-update-cf157e00e3c07a2aPharma Surgeen2026-07-08T15:01:48.000ZSana Biotech heads to EASD with diabetes cell therapy updatehttps://www.pharmaradar360.com/article/is-regeneron-pharmaceuticals-inc-regn-stock-still-a-biotech-leader-after-analyst-1857d66e693af959Pharma Surgeen2026-07-08T14:54:20.000ZIs Regeneron Pharmaceuticals, Inc. (REGN) Stock Still a Biotech Leader After Analyst Price Target Cut?https://www.pharmaradar360.com/article/community-pharmacy-could-help-ease-2-7bn-delayed-discharge-bill-f757f1f3e5116a24Pharma Surgeen2026-07-08T14:49:17.000ZCommunity pharmacy could help ease £2.7bn delayed discharge billhttps://www.pharmaradar360.com/article/europe-will-accelerate-its-review-of-revmed-s-drug-8701ab0d88ea3d66Pharma Surgeen2026-07-08T14:26:47.000ZEurope will accelerate its review of RevMed’s drughttps://www.pharmaradar360.com/article/notifiable-diseases-causative-agents-reports-for-2026-32900b46450305d4Pharma Surgeen2026-07-08T14:21:44.000ZNotifiable diseases: causative agents reports for 2026https://www.pharmaradar360.com/article/novo-nordisk-signs-pact-with-vivani-for-long-lasting-semaglutide-implant-27a367a14db8bfc5Pharma Surgeen2026-07-08T14:15:58.000ZNovo Nordisk signs pact with Vivani for long-lasting semaglutide implanthttps://www.pharmaradar360.com/article/fda-cracks-down-on-illegal-ketamine-sellers-amid-nearing-psychedelic-revolution-8d19aabfb7894451Pharma Surgeen2026-07-08T14:15:58.000ZFDA cracks down on illegal ketamine sellers amid nearing ‘psychedelic revolution’https://www.pharmaradar360.com/article/kalohexis-confidentially-files-ipo-to-back-obesity-and-cachexia-portfolio-939d3455269f177bPharma Surgeen2026-07-08T14:15:00.000ZKalohexis confidentially files IPO to back obesity and cachexia portfoliohttps://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-20-report-data-to-week-19-dat-eb9151086d6e9097Pharma Surgeen2026-07-08T14:11:15.000ZNational flu and COVID-19 surveillance report, week 20 report: data to week 19 (data up to 16 May 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-19-report-data-to-week-18-dat-e6e641100e95a23bPharma Surgeen2026-07-08T14:10:50.000ZNational flu and COVID-19 surveillance report, week 19 report: data to week 18 (data up to 9 May 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-18-report-data-to-week-17-dat-a1383c1237b314a4Pharma Surgeen2026-07-08T14:10:26.000ZNational flu and COVID-19 surveillance report, week 18 report: data to week 17 (data up to 2 May 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-17-report-data-to-week-16-dat-f7b834d10f61e6d1Pharma Surgeen2026-07-08T14:09:59.000ZNational flu and COVID-19 surveillance report, week 17 report: data to week 16 (data up to 25 April 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-16-report-data-to-week-15-dat-42aecb93111f49c0Pharma Surgeen2026-07-08T14:09:32.000ZNational flu and COVID-19 surveillance report, week 16 report: data to week 15 (data up to 18 April 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-15-report-data-to-week-14-dat-373827dc7348e461Pharma Surgeen2026-07-08T14:09:00.000ZNational flu and COVID-19 surveillance report, week 15 report: data to week 14 (data up to 11 April 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-14-report-data-to-week-13-dat-cb071690108f0c13Pharma Surgeen2026-07-08T14:08:32.000ZNational flu and COVID-19 surveillance report, week 14 report: data to week 13 (data up to 4 April 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-13-report-data-to-week-12-dat-f34f7e46e0cbc218Pharma Surgeen2026-07-08T14:07:57.000ZNational flu and COVID-19 surveillance report, week 13 report: data to week 12 (data up to 28 March 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-12-report-data-to-week-11-dat-2248d925c1565b0bPharma Surgeen2026-07-08T14:07:25.000ZNational flu and COVID-19 surveillance report, week 12 report: data to week 11 (data up to 21 March 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-11-report-data-to-week-10-dat-d006ba9728d2f42bPharma Surgeen2026-07-08T14:06:52.000ZNational flu and COVID-19 surveillance report, week 11 report: data to week 10 (data up to 14 March 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-10-report-data-to-week-9-data-65ae1db376478d6cPharma Surgeen2026-07-08T14:06:27.000ZNational flu and COVID-19 surveillance report, week 10 report: data to week 9 (data up to 7 March 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-9-report-data-to-week-8-data-da8467c5e0181f25Pharma Surgeen2026-07-08T14:06:02.000ZNational flu and COVID-19 surveillance report, week 9 report: data to week 8 (data up to 28 February 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-8-report-data-to-week-7-data-9c8304d98790e067Pharma Surgeen2026-07-08T14:05:06.000ZNational flu and COVID-19 surveillance report, week 8 report: data to week 7 (data up to 21 February 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-7-report-data-to-week-6-data-3361a06bc06c6f4bPharma Surgeen2026-07-08T14:04:35.000ZNational flu and COVID-19 surveillance report, week 7 report: data to week 6 (data up to 14 February 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-6-report-data-to-week-5-data-440549a3da1d18e2Pharma Surgeen2026-07-08T14:04:07.000ZNational flu and COVID-19 surveillance report, week 6 report: data to week 5 (data up to 7 February 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-5-report-data-to-week-4-data-2670f011693f7bf0Pharma Surgeen2026-07-08T14:03:41.000ZNational flu and COVID-19 surveillance report, week 5 report: data to week 4 (data up to 31 January 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-4-report-data-to-week-3-data-a451d64aae8e2df2Pharma Surgeen2026-07-08T14:02:59.000ZNational flu and COVID-19 surveillance report, week 4 report: data to week 3 (data up to 24 January 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-3-report-data-to-week-2-data-f473d78c142df7fePharma Surgeen2026-07-08T14:02:32.000ZNational flu and COVID-19 surveillance report, week 3 report: data to week 2 (data up to 17 January 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-2-report-data-to-week-1-data-dd4d02f23e4aa08fPharma Surgeen2026-07-08T13:50:13.000ZNational flu and COVID-19 surveillance report, week 2 report: data to week 1 (data up to 10 January 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-1-report-data-to-week-53-data-72725bd97f2ed752Pharma Surgeen2026-07-08T13:49:36.000ZNational flu and COVID-19 surveillance report, week 1 report: data to week 53 (data up to 3 January 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-51-report-data-to-week-50-dat-8fbe46553359f327Pharma Surgeen2026-07-08T13:48:59.000ZNational flu and COVID-19 surveillance report, week 51 report: data to week 50 (data up to 13 December 2026)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-50-report-data-to-week-49-dat-96d62d373813c277Pharma Surgeen2026-07-08T13:48:33.000ZNational flu and COVID-19 surveillance report, week 50 report: data to week 49 (data up to 6 December 2026)https://www.pharmaradar360.com/article/satellos-intriguing-duchenne-data-raise-hopes-ahead-of-key-readout-c1cfaf80d711d5e7Pharma Surgeen2026-07-08T13:48:20.000ZSatellos’ ‘intriguing’ Duchenne data raise hopes ahead of key readouthttps://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-49-report-data-to-week-48-dat-732f8ad5e6e1472ePharma Surgeen2026-07-08T13:47:57.000ZNational flu and COVID-19 surveillance report, week 49 report: data to week 48 (data up to 29 November 2026)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-48-report-data-to-week-47-dat-35618b8fe7abe17cPharma Surgeen2026-07-08T13:47:25.000ZNational flu and COVID-19 surveillance report, week 48 report: data to week 47 (data up to 22 November 2026)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-47-report-data-to-week-46-dat-60cf61f2680e7827Pharma Surgeen2026-07-08T13:46:47.000ZNational flu and COVID-19 surveillance report, week 47 report: data to week 46 (data up to 15 November 2026)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-46-report-data-to-week-45-dat-19d5c7cb431f423bPharma Surgeen2026-07-08T13:46:05.000ZNational flu and COVID-19 surveillance report, week 46 report: data to week 45 (data up to 8 November 2026)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-45-report-data-to-week-44-dat-2a309b29b8631ad3Pharma Surgeen2026-07-08T13:42:11.000ZNational flu and COVID-19 surveillance report, week 45 report: data to week 44 (data up to 1 November 2026)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-44-report-data-to-week-43-dat-34f205820f4e2f50Pharma Surgeen2026-07-08T13:41:23.000ZNational flu and COVID-19 surveillance report, week 44 report: data to week 43 (data up to 25 October 2026)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-43-report-data-to-week-42-dat-99cbb355a95c8f35Pharma Surgeen2026-07-08T13:39:15.000ZNational flu and COVID-19 surveillance report, week 43 report: data to week 42 (data up to 18 October 2026)https://www.pharmaradar360.com/article/why-is-satellos-bioscience-trading-higher-today-satellos-bioscience-nasdaq-msle-1f7c5626972b3fa4Pharma Surgeen2026-07-08T13:34:20.000ZWhy Is Satellos Bioscience Trading Higher Today? - Satellos Bioscience (NASDAQ:MSLE)https://www.pharmaradar360.com/article/deanna-horner-s-five-year-outlook-for-direct-to-patient-care-1176711a56fa57f9Pharma Surgeen2026-07-08T13:32:58.000ZDeanna Horner's Five-Year Outlook for Direct-to-Patient Carehttps://www.pharmaradar360.com/article/biotech-growth-trust-the-biotech-rebound-powered-by-innovation-valuations-and-ph-dab12e41f9069d0aPharma Surgeen2026-07-08T13:22:30.000ZBiotech Growth Trust: The biotech rebound powered by innovation, valuations and pharma’s patent cliffhttps://www.pharmaradar360.com/article/looking-after-children-and-those-in-early-years-settings-before-and-during-hot-w-5472a0a61f54d041Pharma Surgeen2026-07-08T13:10:03.000ZLooking after children and those in early years settings before and during hot weather: teachers and other educational professionalshttps://www.pharmaradar360.com/article/deliverit-to-build-12m-pharmaceutical-manufacturing-facility-in-sugar-land-5fe5bd8c806a239fPharma Surgeen2026-07-08T13:00:00.000ZDeliverIt to build $12M pharmaceutical manufacturing facility in Sugar Landhttps://www.pharmaradar360.com/article/erexon-intense-blue-vigueur-capsule-b-7704a3f903cb8982Pharma Surgeen2026-07-08T12:58:29.000ZEREXON INTENSE BLUE και VIGUEUR CAPSULE (ΣΙΛΔΕΝΑΦΙΛΗ, ΤΑΔΑΛΑΦΙΛΗ, BΑΡΔΕΝΑΦΙΛΗ)https://www.pharmaradar360.com/article/takeda-pharmaceutical-completes-share-issuance-disposal-under-incentive-plan-30e64b821030c095Pharma Surgeen2026-07-08T12:50:08.000ZTakeda Pharmaceutical Completes Share Issuance, Disposal Under Incentive Planhttps://www.pharmaradar360.com/article/sanner-group-50fa5b88896ed69dPharma Surgeen2026-07-08T12:37:52.000ZSanner Grouphttps://www.pharmaradar360.com/article/gr23193050-martinella-crush-nail-polish-2-x-4ml-581bc0b5682fd599Pharma Surgeen2026-07-08T12:37:14.000ZΑνάκληση της παρτίδας GR23193050 του καλλυντικού προϊόντος βερνίκι νυχιών MARTINELLA CRUSH NAIL POLISH 2 X 4mlhttps://www.pharmaradar360.com/article/the-next-generation-of-medicine-personalized-preventive-and-powered-by-technolog-603fb4dcf99e51bcPharma Surgeen2026-07-08T12:34:09.000ZThe Next Generation of Medicine: Personalized, Preventive, and Powered by Technologyhttps://www.pharmaradar360.com/article/vaccinex-to-show-new-alzheimer-s-biomarker-data-in-london-0bd546cf4fb588b3Pharma Surgeen2026-07-08T12:32:54.000ZVaccinex to show new Alzheimer’s biomarker data in Londonhttps://www.pharmaradar360.com/article/mdd-class-iia-therakos-cellex-photopheresis-procedural-kit-db63e6281b621836Pharma Surgeen2026-07-08T12:32:37.000ZΑνάκληση παρτίδων του Ιατροτεχνολογικού προϊόντος κατηγορίας MDD Class IIa, THERAKOS CELLEX Photopheresis Procedural Kithttps://www.pharmaradar360.com/article/niagen-bioscience-launches-pharmaceutical-program-for-accelerated-aging-and-rare-6e55ccd26baf48dfPharma Surgeen2026-07-08T12:32:00.000ZNiagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseaseshttps://www.pharmaradar360.com/article/diluted-earnings-per-share-diluted-eps-of-veraxa-biotech-ag-nasdaq-vrxaw-48802ab7526d372cPharma Surgeen2026-07-08T12:27:49.000ZDiluted earnings per share (diluted EPS) of Veraxa Biotech AG – NASDAQ:VRXAWhttps://www.pharmaradar360.com/article/10-year-capital-plan-for-health-and-social-care-bb65eafc8b8dfaabPharma Surgeen2026-07-08T12:27:39.000Z10 Year Capital Plan for Health and Social Carehttps://www.pharmaradar360.com/article/c353cdc674a81d83Pharma Surgeen2026-07-08T12:26:25.000ZΕΝΗΜΕΡΩΣΗ ΣΧΕΤΙΚΑ ΜΕ ΤΗΝ ΜΗ ΝΟΜΙΜΗ ΠΑΡΟΥΣΙΑΣΗ, ΠΡΟΩΘΗΣΗ ΚΑΙ ΧΟΡΗΓΗΣΗ «ΕΝΔΟΦΛΕΒΙΩΝ ΘΕΡΑΠΕΙΩΝ»ΩΣ ΣΥΜΠΛΗΡΩΜΑΤΩΝ ΔΙΑΤΡΟΦΗΣhttps://www.pharmaradar360.com/article/rapid-refill-continuous-injection-system-cefc87c31a61078bPharma Surgeen2026-07-08T12:23:58.000ZΑνάκληση παρτίδων του Ιατροτεχνολογικού προϊόντος Rapid Refill Continuous Injection Systemhttps://www.pharmaradar360.com/article/what-is-the-multi-billion-dollar-uk-us-pharmaceutical-deal-9c4ae2cd090de713Pharma Surgeen2026-07-08T12:10:06.000ZWhat is the Multi Billion Dollar UK-US Pharmaceutical Deal?https://www.pharmaradar360.com/article/national-norovirus-and-rotavirus-report-week-4-report-data-to-week-3-data-up-to-2e74c55ab5f0ff0cPharma Surgeen2026-07-08T12:08:29.000ZNational Norovirus and Rotavirus Report, week 4 report: data to week 3 (data up to 24 January 2027)https://www.pharmaradar360.com/article/national-norovirus-and-rotavirus-report-week-3-report-data-to-week-2-data-up-to-66b5e36a07bd61ecPharma Surgeen2026-07-08T12:08:03.000ZNational Norovirus and Rotavirus Report, week 3 report: data to week 2 (data up to 17 January 2027)https://www.pharmaradar360.com/article/beperkte-beschikbaarheid-van-azactam-1-g-en-2-g-poeder-voor-oplossing-voor-injec-7eb4a1294de06995Pharma Surgeen2026-07-08T12:06:44.000ZBeperkte beschikbaarheid van Azactam 1 g en 2 g poeder voor oplossing voor injectie/infusie: aanbevelingen voor artsen-specialisten en ziekenhuisapothekershttps://www.pharmaradar360.com/article/aspen-leader-highlights-importance-of-skills-collaboration-and-technology-in-dri-619d32b8294bed7fPharma Surgeen2026-07-08T12:02:23.000ZAspen leader highlights importance of skills, collaboration and technology in driving manufacturing competitivenesshttps://www.pharmaradar360.com/article/allura-xper-fd10-5ed4d41d78a53269Pharma Surgeen2026-07-08T12:00:00.000ZAllura Xper FD10https://www.pharmaradar360.com/article/joincare-pharmaceutical-group-industry-co-ltd-sponsored-gdr-class-a-regs-897f9783c98b672aPharma Surgeen2026-07-08T11:59:55.000ZJoincare Pharmaceutical Group Industry Co., Ltd. Sponsored GDR Class A RegShttps://www.pharmaradar360.com/article/japan-s-tanabe-sells-pharma-factory-to-towa-pharmaceutical-1f7cd75247d1e109Pharma Surgeen2026-07-08T11:59:27.000ZJapan's Tanabe sells Pharma Factory to Towa Pharmaceuticalhttps://www.pharmaradar360.com/article/pharmaceutical-technology-7c050c9468f47fa7Pharma Surgeen2026-07-08T11:54:26.000ZPharmaceutical Technologyhttps://www.pharmaradar360.com/article/from-semis-to-biotech-a-market-rotation-not-an-ai-reversal-07c1e7869817ee02Pharma Surgeen2026-07-08T11:35:34.000ZFrom Semis to Biotech: A Market Rotation, Not an AI Reversalhttps://www.pharmaradar360.com/article/chemomab-scipher-tie-merger-to-ai-guided-rheumatoid-arthritis-trial-8d5eb3540bc540a3Pharma Surgeen2026-07-08T11:35:00.000ZChemomab, Scipher tie merger to AI-guided rheumatoid arthritis trialhttps://www.pharmaradar360.com/article/immunome-announces-u-s-fda-acceptance-of-new-drug-application-for-varegacestat-f-fd6ca6c361aa80a7Pharma Surgeen2026-07-08T11:30:00.000ZImmunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumorshttps://www.pharmaradar360.com/article/aura-biosciences-announces-appointment-of-jeremy-bender-ph-d-m-b-a-to-board-of-d-012fcb51d275aad8Pharma Surgeen2026-07-08T11:23:16.000ZAura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directorshttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-kobayashi-pharmaceutical-co-ltd-tradegate-koy-78b08374a3ffb121Pharma Surgeen2026-07-08T11:20:05.000ZPrice to earnings forward of Kobayashi Pharmaceutical Co., Ltd. – TRADEGATE:KOYhttps://www.pharmaradar360.com/article/minister-mulls-establishing-national-network-to-collect-expired-medicines-preven-698e453a5f92ac63Pharma Surgeen2026-07-08T11:17:00.000ZMinister mulls establishing national network to collect expired medicines, prevent recirculationhttps://www.pharmaradar360.com/article/rovi-y-la-junta-de-castilla-la-mancha-impulsan-un-marco-de-colaboracion-para-mod-12dcb657bf929dd8Pharma Surgeen2026-07-08T11:00:27.000ZROVI y la Junta de Castilla La Mancha impulsan un marco de colaboración para modernizar servicios sanitarios mediante innovación tecnológicahttps://www.pharmaradar360.com/article/letter-to-the-chair-of-the-food-standards-agency-6bc2df2e1d3b54efPharma Surgeen2026-07-08T11:00:01.000ZLetter to the chair of the Food Standards Agencyhttps://www.pharmaradar360.com/article/food-standards-agency-fsa-economic-growth-goals-ef2f7dbf3dbf38abPharma Surgeen2026-07-08T11:00:01.000ZFood Standards Agency (FSA) economic growth goalshttps://www.pharmaradar360.com/article/fsa-mhra-and-nice-economic-growth-goals-0e0f299be89b45f6Pharma Surgeen2026-07-08T11:00:01.000ZFSA, MHRA and NICE economic growth goalshttps://www.pharmaradar360.com/article/national-institute-for-health-and-care-excellence-nice-economic-growth-goals-88099fabb5625953Pharma Surgeen2026-07-08T11:00:00.000ZNational Institute for Health and Care Excellence (NICE) economic growth goalshttps://www.pharmaradar360.com/article/policy-paper-medicines-and-healthcare-products-regulatory-agency-mhra-economic-g-c0ca8208ee7f614bPharma Surgeen2026-07-08T11:00:00.000ZPolicy paper: Medicines and Healthcare products Regulatory Agency (MHRA) economic growth goalshttps://www.pharmaradar360.com/article/okyo-pharma-reports-positive-feedback-from-fda-type-d-6d6057e2fc8c1dd1Pharma Surgeen2026-07-08T11:00:00.000ZOKYO Pharma Reports Positive Feedback from FDA Type Dhttps://www.pharmaradar360.com/article/fda-feedback-pushes-okyo-pharma-into-phase-3-eye-pain-study-08287565b0a5ffc4Pharma Surgeen2026-07-08T11:00:00.000ZFDA feedback pushes OKYO Pharma into Phase 3 eye-pain studyhttps://www.pharmaradar360.com/article/keenova-s-xiaflex-met-phase-3-goals-in-foot-disorder-trial-ceb29c14c9129a72Pharma Surgeen2026-07-08T11:00:00.000ZKeenova's XIAFLEX met Phase 3 goals in foot disorder trialhttps://www.pharmaradar360.com/article/former-merck-and-nasa-leaders-bring-strategic-expertise-to-spacemd-amid-rising-d-8d67dfcff2cdddecPharma Surgeen2026-07-08T11:00:00.000ZFormer Merck and NASA Leaders Bring Strategic Expertise to SpaceMD Amid Rising Demand for its In-Space Pharmaceutical Development Capabilitieshttps://www.pharmaradar360.com/article/astrazeneca-secures-ex-china-license-for-sino-biopharmaceutical-s-experimental-c-48f0f0f196a1d95bPharma Surgeen2026-07-08T10:56:01.000ZAstraZeneca secures ex-China license for Sino Biopharmaceutical’s experimental COPD drughttps://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-rare-is-up-7-4-after-index-migration-to-russell-2000-a-9e0157fbeb64a870Pharma Surgeen2026-07-08T10:35:21.000ZUltragenyx Pharmaceutical (RARE) Is Up 7.4% After Index Migration To Russell 2000 And Value Benchmarks - Has The Bull Case Changed?https://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-rare-is-up-7-4-after-index-migration-to-russell-2000-a-002aac08317669d2Pharma Surgeen2026-07-08T10:35:19.000ZUltragenyx Pharmaceutical (RARE) Is Up 7.4% After Index Migration To Russell 2000 And Value Benchmarks - Has The Bull Case Changed?https://www.pharmaradar360.com/article/meningococcal-reference-unit-request-form-ceafb7601bb3e0b8Pharma Surgeen2026-07-08T10:12:02.000ZMeningococcal reference unit request formhttps://www.pharmaradar360.com/article/life-sciences-tools-services-stocks-q1-results-benchmarking-10x-genomics-nasdaq-6afbb3c2806af5eaPharma Surgeen2026-07-08T10:06:43.000ZLife Sciences Tools & Services Stocks Q1 Results: Benchmarking 10x Genomics (NASDAQ:TXG)https://www.pharmaradar360.com/article/meningococcal-reference-unit-mru-user-manual-0adcf7a237409564Pharma Surgeen2026-07-08T10:03:36.000ZMeningococcal reference unit (MRU): user manualhttps://www.pharmaradar360.com/article/us-biotech-firm-raises-multi-million-series-b-to-scale-astaxanthin-production-427a35ee79dfb406Pharma Surgeen2026-07-08T09:45:00.000ZUS biotech firm raises multi-million series B to scale astaxanthin productionhttps://www.pharmaradar360.com/article/india-renews-push-for-pharma-market-access-in-china-2372cab3c3b7967bPharma Surgeen2026-07-08T09:45:00.000ZIndia renews push for pharma market access in Chinahttps://www.pharmaradar360.com/article/register-medical-devices-to-place-on-the-market-5d9542deb10b4ffbPharma Surgeen2026-07-08T09:38:38.000ZRegister medical devices to place on the markethttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-timing-pharmaceutical-co-ltd-tpex-6659-f08b02814bf569f2Pharma Surgeen2026-07-08T09:18:49.000ZEnterprise value to EBITDA forward of Timing Pharmaceutical Co. Ltd. – TPEX:6659https://www.pharmaradar360.com/article/new-hospital-programme-annual-report-financial-year-2025-to-2026-c61c57596ef1d3e7Pharma Surgeen2026-07-08T09:13:59.000ZNew Hospital Programme annual report: financial year 2025 to 2026https://www.pharmaradar360.com/article/cover-vaccine-coverage-statistics-data-submission-and-publication-dates-66e32106701ccc1bPharma Surgeen2026-07-08T09:10:31.000ZCOVER vaccine coverage statistics: data submission and publication dateshttps://www.pharmaradar360.com/article/three-biotech-tenants-move-into-former-athenahealth-hq-3760d6c98e422a8cPharma Surgeen2026-07-08T09:00:00.000ZThree biotech tenants move into former athenahealth HQhttps://www.pharmaradar360.com/article/is-biomarin-pharmaceutical-bmrn-still-below-fair-value-after-its-russell-index-a-16918df014fab421Pharma Surgeen2026-07-08T08:38:50.000ZIs BioMarin Pharmaceutical (BMRN) Still Below Fair Value After Its Russell Index Additions?https://www.pharmaradar360.com/article/abl-bio-advances-abl111-to-phase-3-in-first-line-gastric-cancer-paving-the-way-f-2a7eec91771feb0bPharma Surgeen2026-07-08T08:37:16.000ZABL Bio advances ABL111 to Phase 3 in first-line gastric cancer, paving the way for 4-1BB platform licensing-outhttps://www.pharmaradar360.com/article/helix-opens-genomic-cohorts-to-astrazeneca-cdae4d4c2710ead3Pharma Surgeen2026-07-08T08:17:40.000ZHelix opens genomic cohorts to AstraZenecahttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-hunan-er-kang-pharmaceutical-co-ltd-class-a-12b48f10dc97a906Pharma Surgeen2026-07-08T08:14:43.000ZEnterprise value to EBIT forward of Hunan Er-Kang Pharmaceutical Co., Ltd. Class A – SZSE:300267https://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-kobayashi-pharmaceutical-co-ltd-tse-4967-46d68894aa2f619cPharma Surgeen2026-07-08T08:13:18.000ZEnterprise value to revenue forward of Kobayashi Pharmaceutical Co., Ltd. – TSE:4967https://www.pharmaradar360.com/article/suven-life-sciences-allocates-1-85-crore-shares-at-134-to-raise-248-84-crore-5504a7f6f89a11d2Pharma Surgeen2026-07-08T07:58:52.000ZSuven Life Sciences Allocates 1.85 Crore Shares At ₹134 To Raise ₹248.84 Crorehttps://www.pharmaradar360.com/article/always-one-step-ahead-anne-petit-on-making-medicines-happen-99953b4068537be6Pharma Surgeen2026-07-08T07:57:35.000ZAlways one step ahead: Anne Petit on making medicines happenhttps://www.pharmaradar360.com/article/serum-institute-s-dengue-drug-to-undergo-global-trials-early-next-year-5f97f773d071bc5fPharma Surgeen2026-07-08T07:37:04.000ZSerum Institute’s dengue drug to undergo global trials early next yearhttps://www.pharmaradar360.com/article/ligachem-biosciences-pivots-to-late-stage-adc-2-0-invests-1-trillion-won-chosunb-732ff94c938edf4bPharma Surgeen2026-07-08T07:16:00.000ZLigaChem Biosciences pivots to late-stage ADC 2.0, invests 1 trillion won - CHOSUNBIZhttps://www.pharmaradar360.com/article/fda-suspends-heera-sweets-fssai-licence-638c7e070bd9ecb5Pharma Surgeen2026-07-08T07:13:58.000ZFDA suspends Heera Sweets’ FSSAI licencehttps://www.pharmaradar360.com/article/new-cancer-drug-vepdegestrant-gets-fda-approval-3cca99892162c399Pharma Surgeen2026-07-08T07:07:11.000ZNew Cancer Drug Vepdegestrant Gets FDA Approvalhttps://www.pharmaradar360.com/article/1-2026-0fe160449905d401Pharma Surgeen2026-07-08T06:54:42.000ZΤελικές Προτεινόμενες _ Νέα 1ου Τριμήνου 2026 _ Ανατιμολόγηση προϊόντων αναφοράς λόγω λήξης της προστασίας δεδομένων τουςhttps://www.pharmaradar360.com/article/fda-confirms-single-phase-3-trial-sufficient-for-ath434-nda-in-msa-fa63cdd450a0c869Pharma Surgeen2026-07-08T06:54:09.000ZFDA Confirms Single Phase 3 Trial Sufficient for ATH434 NDA in MSAhttps://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-29-report-data-to-week-28-dat-3eecc552c8c5e93ePharma Surgeen2026-07-08T06:49:38.000ZNational flu and COVID-19 surveillance report, week 29 report: data to week 28 (data up to 12 July 2026)https://www.pharmaradar360.com/article/biotech-double-winners-outperform-the-market-with-fundamental-tailwinds-poised-t-e95e5ff58e42d060Pharma Surgeen2026-07-08T06:42:37.000ZBiotech Double Winners Outperform the Market, With Fundamental Tailwinds Poised to Sustain Momentumhttps://www.pharmaradar360.com/article/sarepta-announces-fda-acceptance-of-sndas-for-amondys-45-and-vyondys-53-7be94b2b54c2f9d1Pharma Surgeen2026-07-08T06:37:39.000ZSarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®https://www.pharmaradar360.com/article/takeda-completed-issuance-of-new-shares-and-disposal-of-treasury-shares-under-th-de84d12450044281Pharma Surgeen2026-07-08T06:30:36.000ZTakeda Completed Issuance of New Shares and Disposal of Treasury Shares under the Long-Term Incentive Plan for Company Group Employees Outside of Japan with Partial Forfeiture of Rights Granted to Allottees | Takeda Pharmaceuticalshttps://www.pharmaradar360.com/article/first-aid-a-new-idea-for-the-biotech-act-73f597158e4db8d7Pharma Surgeen2026-07-08T06:28:31.000ZFIRST AID: A new idea for the Biotech Acthttps://www.pharmaradar360.com/article/s2g-hatch-backed-biotech-raises-millions-expands-corbion-ties-5454207d3e5e09eaPharma Surgeen2026-07-08T06:05:15.000ZS2G, Hatch-backed biotech raises millions, expands Corbion tieshttps://www.pharmaradar360.com/article/kintara-kins-price-prediction-2025-2026-will-it-rise-433afe050dc6e270Pharma Surgeen2026-07-08T06:04:17.000ZKintara (KINS) Price Prediction 2025–2026: Will It Rise?https://www.pharmaradar360.com/article/avacta-appoints-healthcare-executive-patrick-vink-as-deputy-chairman-of-the-boar-658571a1441a8f91Pharma Surgeen2026-07-08T06:03:17.000ZAvacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directorshttps://www.pharmaradar360.com/article/china-s-biotech-boom-ras-targeted-drugs-challenge-us-dominance-3c2b6c6acdf8bdadPharma Surgeen2026-07-08T06:00:12.000ZChina’s biotech boom: RAS-targeted drugs challenge US dominancehttps://www.pharmaradar360.com/article/why-is-sichuan-kelun-biotech-stock-sliding-today-5b87bf8c57895db1Pharma Surgeen2026-07-08T05:55:53.000ZWhy is Sichuan Kelun Biotech stock sliding today?https://www.pharmaradar360.com/article/d-d-pharmatech-earns-milestone-as-partner-advances-fap-pet-imaging-agent-into-ph-933b0ac4d4800d5fPharma Surgeen2026-07-08T05:49:56.000ZD&D Pharmatech earns milestone as partner advances FAP PET imaging agent into phase 2https://www.pharmaradar360.com/article/d-d-pharmatech-earns-milestone-as-partner-advances-fap-pet-imaging-agent-into-ph-df5f53eb9fd8ca35Pharma Surgeen2026-07-08T05:24:37.000ZD&D Pharmatech earns milestone as partner advances FAP PET imaging agent into phase 2https://www.pharmaradar360.com/article/woojung-bio-changes-name-to-kolmar-biotech-after-joining-kolmar-group-08ffde28665ecfc1Pharma Surgeen2026-07-08T05:17:10.000ZWoojung Bio changes name to Kolmar BioTech after joining Kolmar Grouphttps://www.pharmaradar360.com/article/vktx-vs-bcrx-which-biotech-takeover-favorite-offers-more-upside-after-vertex-s-1-3f511bc74011a51fPharma Surgeen2026-07-08T05:14:31.000ZVKTX Vs BCRX: Which Biotech Takeover Favorite Offers More Upside After Vertex’s $10B CRNX Deal?https://www.pharmaradar360.com/article/vktx-vs-bcrx-which-biotech-takeover-favorite-offers-more-upside-after-vertex-s-1-9f358803ca3b9132Pharma Surgeen2026-07-08T05:11:00.000ZVKTX Vs BCRX: Which Biotech Takeover Favorite Offers More Upside After Vertex’s $10B CRNX Deal?https://www.pharmaradar360.com/article/ono-pharmaceutical-tse-4528-could-be-33-undervalued-as-opdivo-and-pipeline-progr-546c5af262a6f57bPharma Surgeen2026-07-08T05:08:14.000ZOno Pharmaceutical (TSE:4528) Could Be 33% Undervalued As Opdivo And Pipeline Progress Buildhttps://www.pharmaradar360.com/article/aribio-nears-phase-3-results-for-oral-alzheimer-s-drug-mason-capital-s-investmen-db513a87f3646f6fPharma Surgeen2026-07-08T04:55:17.000ZAribio Nears Phase 3 Results for Oral Alzheimer’s Drug... Mason Capital’s Investment Performance Becomes Visiblehttps://www.pharmaradar360.com/article/bpc-157-not-fda-approved-the-u-s-food-and-drug-administration-is-moving-toward-a-a63624218fcfc954Pharma Surgeen2026-07-08T04:53:59.000Zbpc 157 not fda approved The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies ⁠to produce more than a dozen injectable peptides that were banned because of ⁠potentially significant safety risks, the New Yorkhttps://www.pharmaradar360.com/article/exposeiq-juryfit-helps-pharmaceutical-litigation-teams-transform-jury-selection-c907d646e69d1cfePharma Surgeen2026-07-08T04:24:13.000ZExposeIQ JuryFit Helps Pharmaceutical Litigation Teams Transform Jury Selection Strategy with Human-Verified Insightshttps://www.pharmaradar360.com/article/geared-power-biotech-ceo-gary-kellstrom-jr-featured-on-going-beyond-the-deal-pod-2c9efd48b0a5a176Pharma Surgeen2026-07-08T04:18:00.000ZGeared Power BioTech CEO, Gary Kellstrom, Jr. Featured on 'Going Beyond the Deal' Podcast with J. Michael Fischer, Jr.https://www.pharmaradar360.com/article/hc-questions-fda-push-to-invoke-mcoca-in-food-safety-cases-across-maha-fcb9e5bd41c90abcPharma Surgeen2026-07-08T03:43:08.000ZHC questions FDA push to invoke MCOCA in food safety cases across Mahahttps://www.pharmaradar360.com/article/three-pharmaceutical-stocks-to-consider-buying-to-profit-from-a-weight-loss-tren-b5783866e0fae922Pharma Surgeen2026-07-08T02:40:11.000ZThree Pharmaceutical Stocks to Consider Buying to Profit from a Weight-Loss Trendhttps://www.pharmaradar360.com/article/pangea-pharmaceuticals-advances-its-next-phase-of-growth-with-an-expanding-comme-6e83c8b200dcb713Pharma Surgeen2026-07-08T01:40:21.000ZPangea Pharmaceuticals Advances Its Next Phase of Growth With an Expanding Commercial Portfoliohttps://www.pharmaradar360.com/article/medipost-doses-first-patient-in-u-s-phase-3-trial-for-knee-osteoarthritis-cell-t-b60b100516ced2b9Pharma Surgeen2026-07-08T01:17:00.000ZMedipost Doses First Patient in U.S. Phase 3 Trial for Knee Osteoarthritis Cell Therapy 'Cartistem'https://www.pharmaradar360.com/article/medipost-s-cartistem-begins-u-s-phase-3-doses-first-patient-5570110fb340b198Pharma Surgeen2026-07-08T00:38:25.000ZMedipost's Cartistem Begins U.S. Phase 3, Doses First Patienthttps://www.pharmaradar360.com/article/the-fda-must-reinstate-safety-restrictions-for-abortion-drug-82473f95bf17f7e6Pharma Surgeen2026-07-08T00:01:56.000ZThe FDA Must Reinstate Safety Restrictions for Abortion Drughttps://www.pharmaradar360.com/article/moderna-filed-form-8-k-738819d8b969f9c5Pharma Surgeen2026-07-08T00:00:00.000ZModerna filed Form 8-Khttps://www.pharmaradar360.com/article/view-all-in-depth-f57711315ba4a48ePharma Surgeen2026-07-08T00:00:00.000ZView all in-depthhttps://www.pharmaradar360.com/article/novel-life-saving-liver-procedure-recommended-potentially-enabling-hundreds-more-fd16c74af776d6dcPharma Surgeen2026-07-08T00:00:00.000ZNovel life-saving liver procedure recommended, potentially enabling hundreds more transplantshttps://www.pharmaradar360.com/article/view-all-news-articles-c59e11b18e2ad94dPharma Surgeen2026-07-08T00:00:00.000ZView all news articleshttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-5bc0a73e5b42e5c9Pharma Surgeen2026-07-08T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-09bdc229ae55589aPharma Surgeen2026-07-08T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-23c742c1413e6e11Pharma Surgeen2026-07-08T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-1560d4e1d877f904Pharma Surgeen2026-07-08T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-5c30380fa91bc817Pharma Surgeen2026-07-08T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-a52c0766eb756ab2Pharma Surgeen2026-07-08T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-21a968c1afa6f5d2Pharma Surgeen2026-07-08T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-ec8bec6b45dad569Pharma Surgeen2026-07-08T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-e8ba05c60e7ca7d8Pharma Surgeen2026-07-08T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-0c4a79041fd9b089Pharma Surgeen2026-07-08T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-f76455af0e4a5724Pharma Surgeen2026-07-08T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-102990df460508fePharma Surgeen2026-07-08T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake-d5b5fd388de2b5fbPharma Surgeen2026-07-08T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/home-page-0a45c5dd28ad1209Pharma Surgeen2026-07-08T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/schedules-of-controlled-substances-placement-of-tianeptine-in-schedule-i-b7e74286d39bdc0dPharma Surgeen2026-07-08T00:00:00.000ZSchedules of Controlled Substances: Placement of Tianeptine in Schedule Ihttps://www.pharmaradar360.com/article/cellular-tissue-and-gene-therapies-advisory-committee-notice-of-meeting-establis-f5269d09f9bc98a4Pharma Surgeen2026-07-08T00:00:00.000ZCellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Biologics License Application (BLA) 125827, From Replimune, Inc. for Vusolimogene Oderparepvechttps://www.pharmaradar360.com/article/proposed-collection-60-day-comment-request-generic-clearance-for-the-collection-91294e50f67440a0Pharma Surgeen2026-07-08T00:00:00.000ZProposed Collection; 60-Day Comment Request: Generic Clearance for the Collection of Customer Participation and Performance Management With NIH Programs, Products, and Services (Office of the Director)https://www.pharmaradar360.com/article/government-owned-invention-available-for-license-method-of-detecting-circulating-2211f39fd3f4154ePharma Surgeen2026-07-08T00:00:00.000ZGovernment Owned Invention Available for License: Method of Detecting Circulating Cell-Free HPV 6 and 11 DNA in Patients Afflicted With Diseases Caused by Chronic HPV 6 or 11 Infection and Use Thereofhttps://www.pharmaradar360.com/article/government-owned-invention-available-for-license-generating-conditional-and-reve-8316d35061ffc105Pharma Surgeen2026-07-08T00:00:00.000ZGovernment Owned Invention Available for License: Generating Conditional and Reverse Conditional Loss-of-Function Alleles in Mouse Casq2https://www.pharmaradar360.com/article/medicare-program-announcement-of-the-advisory-panel-on-hospital-outpatient-payme-5c1e6154f8d9d08cPharma Surgeen2026-07-08T00:00:00.000ZMedicare Program; Announcement of the Advisory Panel on Hospital Outpatient Payment Meeting-August 24, 2026https://www.pharmaradar360.com/article/medical-device-user-fee-amendments-public-meeting-request-for-comments-7a49cc926bbb6ad4Pharma Surgeen2026-07-08T00:00:00.000ZMedical Device User Fee Amendments; Public Meeting; Request for Commentshttps://www.pharmaradar360.com/article/aripiprazole-versus-bupropion-augmentation-in-patients-with-anxious-depression-r-cf3372bb7dd2b5f9Pharma Surgeen2026-07-08T00:00:00.000ZAripiprazole versus Bupropion Augmentation in Patients with Anxious Depression Resistant to Selective Serotonin Reuptake Inhibitors: A Randomized, Prospective, Open-label, Multicenter Studyhttps://www.pharmaradar360.com/article/reviewer-2-public-review-single-cell-transcriptome-wide-mendelian-randomization-20b6ae82d797fb20Pharma Surgeen2026-07-08T00:00:00.000ZReviewer #2 (Public review): Single-cell transcriptome-wide Mendelian randomization and colocalization analyses reveal immune-cell-specific mechanisms and actionable drug targets in prostate cancerhttps://www.pharmaradar360.com/article/single-cell-transcriptome-wide-mendelian-randomization-and-colocalization-analys-8a01cc8c8ca0b509Pharma Surgeen2026-07-08T00:00:00.000ZSingle-cell transcriptome-wide Mendelian randomization and colocalization analyses reveal immune-cell-specific mechanisms and actionable drug targets in prostate cancerhttps://www.pharmaradar360.com/article/analise-clinica-e-epidemiologica-de-pacientes-oncologicos-em-instituicao-privada-bf64f730fb9d28f6Pharma Surgeen2026-07-08T00:00:00.000ZAnálise clínica e epidemiológica de pacientes oncológicos em instituição privada em Maceió- ALhttps://www.pharmaradar360.com/article/cbd-and-passion-flower-for-anxiety-clinical-use-considerations-d93aba7a97781571Pharma Surgeen2026-07-08T00:00:00.000ZCBD and Passion Flower for Anxiety: Clinical Use Considerationshttps://www.pharmaradar360.com/article/diversity-of-endophytic-fungi-associated-with-the-aerial-roots-of-ficus-benghale-0b0f44619ee5af70Pharma Surgeen2026-07-08T00:00:00.000ZDiversity of Endophytic Fungi Associated with the Aerial Roots of Ficus benghalensis L. in the Sacred Groves of Ponnamaravathi, Pudukkottai District, Tamil Nadu, Indiahttps://www.pharmaradar360.com/article/hyaluronidase-in-aesthetic-plastic-surgery-clinical-uses-safety-ultrasound-guida-e51108891367ee49Pharma Surgeen2026-07-08T00:00:00.000ZHyaluronidase in Aesthetic Plastic Surgery: Clinical Uses, Safety, Ultrasound Guidance, And Current Controversieshttps://www.pharmaradar360.com/article/rothmund-thomson-syndrome-revisited-expanding-the-genotypic-spectrum-deciphering-79205d672374fe0bPharma Surgeen2026-07-08T00:00:00.000ZRothmund-Thomson Syndrome Revisited: Expanding the Genotypic Spectrum, Deciphering RECQL4-Related Pathomechanisms, And Redefining Long-Term Surveillance Strategies for An Underrecognized Genodermatosishttps://www.pharmaradar360.com/article/epigenetic-regulation-in-acute-myeloid-leukemia-molecular-mechanisms-and-clinica-33bf83c7fabd96e1Pharma Surgeen2026-07-08T00:00:00.000ZEpigenetic Regulation in Acute Myeloid Leukemia: Molecular Mechanisms and Clinical Implicationshttps://www.pharmaradar360.com/article/case-report-when-access-is-limited-using-cyp3a4-inhibition-to-maintain-clinical-f5d65d53f5048cdePharma Surgeen2026-07-08T00:00:00.000ZCase Report: When access is limited: using CYP3A4 inhibition to maintain clinical benefit from elexacaftor/tezacaftor/ivacaftorhttps://www.pharmaradar360.com/article/case-report-from-misdiagnosis-to-successful-treatment-using-mepolizumab-in-anca-1b61c157d8ed1a2cPharma Surgeen2026-07-08T00:00:00.000ZCase Report: From misdiagnosis to successful treatment using mepolizumab in ANCA-negative severe EGPA—clinical lessons in eosinophil-targeted therapyhttps://www.pharmaradar360.com/article/clinical-and-immunological-characterization-of-nfkb1-haploinsufficiency-in-japan-4144db110006ee40Pharma Surgeen2026-07-08T00:00:00.000ZClinical and immunological characterization of NFKB1 haploinsufficiency in Japanhttps://www.pharmaradar360.com/article/clinical-characteristics-and-risk-factors-of-atrial-fibrillation-detection-after-99fb4f834fbf47dfPharma Surgeen2026-07-08T00:00:00.000ZClinical characteristics and risk factors of atrial fibrillation detection after acute ischemic strokehttps://www.pharmaradar360.com/article/divergence-in-surface-protein-exposure-between-reference-and-clinical-derived-ca-371721d81f08e23cPharma Surgeen2026-07-08T00:00:00.000ZDivergence in surface protein exposure between reference and clinical-derived Candida glabrata (Nakaseomyces glabratus) strains (CBS138 vs. BG2) – a preliminary proteomic perspectivehttps://www.pharmaradar360.com/article/effects-of-breaking-up-prolonged-sitting-with-an-office-based-exercise-program-o-247f4c2f20cc7684Pharma Surgeen2026-07-08T00:00:00.000ZEffects of Breaking Up Prolonged Sitting with an Office-Based Exercise Program on Sitting Time, Physical Activity, Musculoskeletal Discomfort, and Stress in Office Workers: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/the-gut-microbiome-tumor-microenvironment-axis-in-immunotherapy-response-mechani-93920ee5011ed1c6Pharma Surgeen2026-07-08T00:00:00.000ZThe gut microbiome–tumor microenvironment axis in immunotherapy response: Mechanistic insights and clinical implicationshttps://www.pharmaradar360.com/article/to-study-ten-year-survival-for-patients-undergoing-coronary-endarterectomy-in-pa-aa5c4b8cb993d8c1Pharma Surgeen2026-07-08T00:00:00.000ZTO STUDY TEN-YEAR SURVIVAL FOR PATIENTS UNDERGOING CORONARY ENDARTERECTOMY IN PATIENTS WITH CORONARY ARTERY DISEASEhttps://www.pharmaradar360.com/article/the-role-of-thyroid-disease-and-other-biomarkers-in-invasive-breast-cancer-a-3-y-9dfc551c17aef9c0Pharma Surgeen2026-07-08T00:00:00.000ZThe Role of Thyroid Disease and Other Biomarkers in Invasive Breast Cancer: A 3-year Retrospective Comparative Studyhttps://www.pharmaradar360.com/article/clinical-data-review-of-the-cathtronix-intravascular-pta-balloon-dilatation-cath-6d5223a6ec85b9b6Pharma Surgeen2026-07-08T00:00:00.000ZClinical Data Review of the CATHTRONIX Intravascular PTA Balloon Dilatation Catheter: Clinical Safety, Clinical Performance and Clinical Benefit Evaluation with Hospital-Based Clinical Follow-Up and State-of-the-Art Literature Appraisalhttps://www.pharmaradar360.com/article/large-language-models-for-world-health-organization-uppsala-monitoring-centre-dr-0a951801cbc40c36Pharma Surgeen2026-07-08T00:00:00.000ZLarge Language Models for World Health Organization–Uppsala Monitoring Centre Drug–Adverse Event Causality Assessment Using Food and Drug Administration Adverse Event Reporting System Cases: Comparative Performance Studyhttps://www.pharmaradar360.com/article/an-evidence-based-cognitive-stimulation-and-physical-activity-intervention-to-de-276415f7a6028a13Pharma Surgeen2026-07-08T00:00:00.000ZAn Evidence-Based Cognitive Stimulation and Physical Activity Intervention to Delay Aging-Related Decline: Protocol for a Randomized Controlled Trialhttps://www.pharmaradar360.com/article/in-vivo-evaluations-of-drug-delivery-to-the-brain-e04904ce244e216bPharma Surgeen2026-07-08T00:00:00.000ZIn Vivo Evaluations of Drug Delivery to the Brainhttps://www.pharmaradar360.com/article/exosomes-for-drug-delivery-to-the-brain-d3554e43480613bePharma Surgeen2026-07-08T00:00:00.000ZExosomes for Drug Delivery to the Brainhttps://www.pharmaradar360.com/article/association-between-the-zju-index-and-clinical-outcomes-in-patients-with-acute-m-78de92bbd1b47020Pharma Surgeen2026-07-08T00:00:00.000ZAssociation between the ZJU Index and clinical outcomes in patients with acute myocardial infarctionhttps://www.pharmaradar360.com/article/artificial-intelligence-in-shoulder-arthroplasty-latest-concepts-and-clinical-in-438ad71706a474c1Pharma Surgeen2026-07-08T00:00:00.000ZArtificial intelligence in shoulder arthroplasty: latest concepts and clinical integrationhttps://www.pharmaradar360.com/article/clinical-rationale-for-thymic-restoration-in-adult-immunosenescence-88ba1878e1e781c2Pharma Surgeen2026-07-08T00:00:00.000ZClinical rationale for thymic restoration in adult immunosenescencehttps://www.pharmaradar360.com/article/dental-students-perceptions-of-preclinical-and-clinical-prosthodontic-education-0578482fe8a87a01Pharma Surgeen2026-07-08T00:00:00.000ZDental students’ perceptions of preclinical and clinical prosthodontic education: a cross-sectional surveyhttps://www.pharmaradar360.com/article/the-effect-of-foraminal-enlargement-and-irrigant-activation-technique-on-post-op-591d225bece4520fPharma Surgeen2026-07-08T00:00:00.000ZThe effect of foraminal enlargement and irrigant activation technique on post-operative pain in necrotic teeth - a clinical studyhttps://www.pharmaradar360.com/article/clinical-characteristics-and-risk-factors-for-mortality-in-pulmonary-mucormycosi-7fc5c0144ba5ef8bPharma Surgeen2026-07-08T00:00:00.000ZClinical characteristics and risk factors for mortality in pulmonary mucormycosis among patients with non-hematologic malignancieshttps://www.pharmaradar360.com/article/continuous-adductor-canal-block-versus-continuous-femoral-nerve-block-for-analge-2c2bb04f6c38d030Pharma Surgeen2026-07-08T00:00:00.000ZContinuous adductor canal block versus continuous femoral nerve block for analgesia after open reduction and internal fixation of patellar fractures: a randomized controlled trialhttps://www.pharmaradar360.com/article/incidence-and-clinical-characteristics-of-taxane-induced-peripheral-neuropathy-r-f8e55a8f9f0cd0daPharma Surgeen2026-07-08T00:00:00.000ZIncidence and clinical characteristics of taxane-induced peripheral neuropathy requiring treatment in patients with breast cancerhttps://www.pharmaradar360.com/article/clinical-triage-of-individuals-with-warning-symptoms-of-imminent-cardiac-arrest-58e558e190cb4c96Pharma Surgeen2026-07-08T00:00:00.000ZClinical Triage of Individuals With Warning Symptoms of Imminent Cardiac Arresthttps://www.pharmaradar360.com/article/impact-of-vitamin-d-on-the-colon-cancer-immune-microenvironment-results-of-a-ran-6a5c80dd8918b87fPharma Surgeen2026-07-08T00:00:00.000ZImpact of vitamin D on the colon cancer immune microenvironment: results of a randomized clinical trial of preoperative vitamin D supplementation in patients with stage I-III colon cancerhttps://www.pharmaradar360.com/article/hepatitis-b-virus-core-immunoglobulin-m-false-positive-more-common-than-true-375e3a9983c04edfPharma Surgeen2026-07-08T00:00:00.000ZHepatitis B virus core immunoglobulin M: false positive more common than truehttps://www.pharmaradar360.com/article/a-sensitive-and-reduced-cost-culture-medium-for-recovery-of-i-clostridioides-dif-c2682e2326b482c7Pharma Surgeen2026-07-08T00:00:00.000ZA sensitive and reduced-cost culture medium for recovery of <i>Clostridioides difficile</i> isolates with reduced fidaxomicin susceptibility from stoolhttps://www.pharmaradar360.com/article/av-node-ablation-and-conduction-system-pacing-versus-biventricular-pacing-in-pat-f838622e8543347aPharma Surgeen2026-07-08T00:00:00.000ZAV Node Ablation and Conduction System Pacing Versus Biventricular Pacing in Patients With AF and HFhttps://www.pharmaradar360.com/article/right-aortic-arch-and-double-arch-current-clinical-challenges-9ec936663d703351Pharma Surgeen2026-07-08T00:00:00.000ZRight aortic arch and double arch: current clinical challengeshttps://www.pharmaradar360.com/article/a-point-prevalence-survey-on-antibiotic-dispensing-practices-identifies-targets-0fe0ccc8d4f76306Pharma Surgeen2026-07-08T00:00:00.000ZA point prevalence survey on antibiotic dispensing practices identifies targets for quality improvement of antimicrobial stewardship in community pharmacies in Dar es Salaam, Tanzaniahttps://www.pharmaradar360.com/article/belantamab-mafodotin-a-bcma-directed-antibody-drug-conjugate-for-multiple-myelom-e42fbb112788e56bPharma Surgeen2026-07-08T00:00:00.000ZBelantamab mafodotin, a BCMA-directed antibody-drug conjugate for multiple myelomahttps://www.pharmaradar360.com/article/therapeutic-use-of-cardioselective-beta-blockers-for-patients-with-chronic-obstr-b5b664640af1ead9Pharma Surgeen2026-07-08T00:00:00.000ZTherapeutic use of cardioselective beta-blockers for patients with chronic obstructive pulmonary disease: a review of current clinical evidencehttps://www.pharmaradar360.com/article/multilevel-brain-heart-interaction-correlates-with-suicidal-ideation-in-first-ep-87953b4158e8dcdfPharma Surgeen2026-07-08T00:00:00.000ZMultilevel brain heart interaction correlates with suicidal ideation in first episode drug naive major depressive disorderhttps://www.pharmaradar360.com/article/olaparib-in-hr-deficient-metastatic-triple-negative-breast-and-platinum-sensitiv-da509645cccf1484Pharma Surgeen2026-07-08T00:00:00.000ZOlaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trialhttps://www.pharmaradar360.com/article/fda-approves-novel-cell-therapy-made-with-haematopoietic-stem-cells-tregs-and-t-bf0b6424128c3206Pharma Surgeen2026-07-08T00:00:00.000ZFDA approves novel cell therapy made with haematopoietic stem cells, Tregs and T cellshttps://www.pharmaradar360.com/article/car-t-cell-therapy-for-solid-cancer-scores-first-approval-in-china-de2524c2440e8451Pharma Surgeen2026-07-08T00:00:00.000ZCAR T cell therapy for solid cancer scores first approval in Chinahttps://www.pharmaradar360.com/article/hydrogen-and-fluorine-functionalized-germagraphene-quantum-dots-dft-studies-and-58e4fe20a39e839bPharma Surgeen2026-07-08T00:00:00.000ZHydrogen- and Fluorine-Functionalized Germagraphene Quantum Dots: DFT Studies and Implications for Anticancer Drug Deliveryhttps://www.pharmaradar360.com/article/killing-the-messiah-the-trial-and-crucifixion-of-jesus-of-nazareth-by-nathaniel-aafd4264d4178228Pharma Surgeen2026-07-08T00:00:00.000ZKilling the Messiah: The Trial and Crucifixion of Jesus of Nazareth By Nathaniel J. Andrade, Oxford: Oxford University Press, 2025. 273 pp.https://www.pharmaradar360.com/article/the-costs-of-partner-engagement-in-research-opportunities-for-pragmatic-research-a34f36841467805cPharma Surgeen2026-07-08T00:00:00.000ZThe Costs of Partner Engagement in Research: Opportunities for Pragmatic Research, Implementation Science, and the Science of Engagementhttps://www.pharmaradar360.com/article/epidemiological-landscape-and-clinical-heterogeneity-of-primary-pancreatic-lymph-b5357a25b2581913Pharma Surgeen2026-07-08T00:00:00.000ZEpidemiological landscape and clinical heterogeneity of primary pancreatic lymphoma: a population-based studyhttps://www.pharmaradar360.com/article/exploring-the-mechanism-by-which-triphenyl-phosphate-promotes-malignant-phenotyp-72da33fbc150b22fPharma Surgeen2026-07-08T00:00:00.000ZExploring the mechanism by which triphenyl phosphate promotes malignant phenotypes in bladder and kidney cancer through MMP9 based on bioinformatics analysis and experimental validationhttps://www.pharmaradar360.com/article/low-dose-not-low-risk-potential-adrenal-suppression-identified-by-a-risk-based-a-810a5cdc0a3d5075Pharma Surgeen2026-07-08T00:00:00.000ZLow-dose, not low-risk: potential adrenal suppression identified by a risk-based approach to ACTH testinghttps://www.pharmaradar360.com/article/effects-of-exercise-on-physical-function-and-pain-in-adults-with-rheumatoid-arth-1b71d2532497a0a6Pharma Surgeen2026-07-08T00:00:00.000ZEffects of exercise on physical function and pain in adults with rheumatoid arthritis: an exit meta-analysis of randomized controlled trialshttps://www.pharmaradar360.com/article/towards-multidisciplinary-summarization-of-hospital-stays-efficient-sentence-lev-d591ebb85f9cd97aPharma Surgeen2026-07-08T00:00:00.000ZTowards Multidisciplinary Summarization of Hospital Stays: Efficient Sentence-Level Clinical Section Categorizationhttps://www.pharmaradar360.com/article/machine-learning-for-early-prediction-of-gestational-diabetes-mellitus-using-rou-a41f7c63f42f9b7fPharma Surgeen2026-07-08T00:00:00.000ZMachine Learning for Early Prediction of Gestational Diabetes Mellitus Using Routinely Collected Clinical Datahttps://www.pharmaradar360.com/article/ontology-aligned-clinical-ner-in-emergency-medicine-using-weak-supervision-74e1bdbd9f416fa0Pharma Surgeen2026-07-08T00:00:00.000ZOntology-Aligned Clinical NER in Emergency Medicine Using Weak Supervisionhttps://www.pharmaradar360.com/article/reasoning-enhanced-rare-event-prediction-with-balanced-outcome-correction-for-cl-2a90ce6b58b634ddPharma Surgeen2026-07-08T00:00:00.000ZReasoning-Enhanced Rare-Event Prediction with Balanced Outcome Correction for Clinical Decision Supporthttps://www.pharmaradar360.com/article/transforming-hospitals-with-artificial-intelligence-applications-in-clinical-edu-a5b87ec1a8845c51Pharma Surgeen2026-07-08T00:00:00.000ZTransforming Hospitals with Artificial Intelligence: Applications in Clinical Education and Patient Carehttps://www.pharmaradar360.com/article/bone-stability-after-regenerative-peri-implantitis-treatment-a-10-year-follow-up-86841b38e9ab986cPharma Surgeen2026-07-08T00:00:00.000ZBone stability after regenerative peri‐implantitis treatment: A 10‐year follow‐up case studyhttps://www.pharmaradar360.com/article/nct07691255-melanoma-brain-metastasis-treated-with-cyberknife-96f3237640be84f1Pharma Surgeen2026-07-08T00:00:00.000ZNCT07691255: MELanoma Brain Metastasis Treated With CYberknifehttps://www.pharmaradar360.com/article/nct07691216-retrospective-observational-multicenter-study-on-the-burden-of-hospi-c8bb24684966c6f7Pharma Surgeen2026-07-08T00:00:00.000ZNCT07691216: Retrospective Observational Multicenter Study on the Burden of Hospitalized Patients With Respiratory Tract Infectionhttps://www.pharmaradar360.com/article/nct07690774-ai-assisted-versus-conventional-orthodontic-diagnosis-and-treatment-1583363039a89c51Pharma Surgeen2026-07-08T00:00:00.000ZNCT07690774: AI-Assisted Versus Conventional Orthodontic Diagnosis and Treatment Planninghttps://www.pharmaradar360.com/article/nct07689539-trial-of-dn022150-versus-chemotherapy-in-previously-treated-advanced-674234fe14f14278Pharma Surgeen2026-07-08T00:00:00.000ZNCT07689539: Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutationhttps://www.pharmaradar360.com/article/nct07689279-selection-of-transcatheter-heart-valve-with-intermediate-sizing-in-p-5db2acb471fbdc03Pharma Surgeen2026-07-08T00:00:00.000ZNCT07689279: Selection of Transcatheter Heart vaLve With Intermediate Sizing in Patients With Severe Aortic Stenosis Treated With Transcatheter Aortic Valve Replacementhttps://www.pharmaradar360.com/article/nct07680114-overnight-thalamic-tes-ti-to-modulate-sleep-spindles-in-individuals-50de684cee425c36Pharma Surgeen2026-07-08T00:00:00.000ZNCT07680114: Overnight Thalamic TES-TI to Modulate Sleep Spindles in Individuals With Schizophrenia Spectrum Disorders and Matched Healthy Controlshttps://www.pharmaradar360.com/article/nct07675785-pfspz-larc2-vaccine-in-women-of-child-bearing-potential-wocbp-in-mal-0ba7de91e40ac6eaPharma Surgeen2026-07-08T00:00:00.000ZNCT07675785: PfSPZ-LARC2 Vaccine in Women of Child-bearing Potential (WOCBP) in Malihttps://www.pharmaradar360.com/article/nct07620951-material-balance-of-14c-zorifertinib-in-healthy-adult-male-participa-1323113752e833afPharma Surgeen2026-07-08T00:00:00.000ZNCT07620951: Material Balance of [14C]Zorifertinib in Healthy Adult Male Participants in Chinahttps://www.pharmaradar360.com/article/nct07545837-health-and-wellness-coaching-to-improve-adherence-to-healthy-habits-8491e84bb56771c4Pharma Surgeen2026-07-08T00:00:00.000ZNCT07545837: Health and Wellness Coaching to Improve Adherence to Healthy Habits and Treatment Plans in Papillary and Follicular Thyroid Cancer Survivorshttps://www.pharmaradar360.com/article/nct07443930-musicians-health-education-in-d-a-ch-9ea595880d2f70dcPharma Surgeen2026-07-08T00:00:00.000ZNCT07443930: Musicians' Health Education in D-A-CHhttps://www.pharmaradar360.com/article/nct07416188-novel-indenoisoquinolone-cmyc-topoisomerase-1-inhibitor-lmp744-in-re-dcf6d8e23b23af45Pharma Surgeen2026-07-08T00:00:00.000ZNCT07416188: Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastomahttps://www.pharmaradar360.com/article/nct07406620-entropy-based-physiological-signal-analysis-in-patients-with-obstruc-580cebaa0ce7631aPharma Surgeen2026-07-08T00:00:00.000ZNCT07406620: Entropy-based Physiological Signal Analysis in Patients With Obstructive Sleep Apnoeahttps://www.pharmaradar360.com/article/nct07355062-a-study-to-evaluate-the-efficacy-and-safety-of-veverimer-for-the-tre-f1f395082faf25baPharma Surgeen2026-07-08T00:00:00.000ZNCT07355062: A Study to Evaluate the Efficacy and Safety of Veverimer for the Treatment of Metabolic Acidosishttps://www.pharmaradar360.com/article/nct07339033-trial-of-device-that-is-not-approved-or-cleared-by-the-u-s-fda-e56c5d4728280508Pharma Surgeen2026-07-08T00:00:00.000ZNCT07339033: [Trial of device that is not approved or cleared by the U.S. FDA]https://www.pharmaradar360.com/article/nct06933251-pcsk9-inhibitor-and-pd-1-inhibitor-combined-with-neoadjuvant-chemora-02280c691771f0c3Pharma Surgeen2026-07-08T00:00:00.000ZNCT06933251: PCSK9 Inhibitor and PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy for pMMR/MSS Locally Advanced Rectal Cancerhttps://www.pharmaradar360.com/article/nct06909357-creation-of-an-infrastructure-to-support-delivery-of-mhealth-interve-91ee37745d2dd9cbPharma Surgeen2026-07-08T00:00:00.000ZNCT06909357: Creation of an Infrastructure to Support Delivery of mHealth Interventions for Cancer Patientshttps://www.pharmaradar360.com/article/nct06875310-a-study-of-adagrasib-plus-pembrolizumab-plus-chemotherapy-vs-placebo-b1d1bb9e85e90d8cPharma Surgeen2026-07-08T00:00:00.000ZNCT06875310: A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)https://www.pharmaradar360.com/article/nct06694454-neoadjuvant-inhaled-azacytidine-with-platinum-based-chemotherapy-and-0c2ce5ad67f1e6f8Pharma Surgeen2026-07-08T00:00:00.000ZNCT06694454: Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)https://www.pharmaradar360.com/article/nct06424769-improving-outcomes-and-reducing-disparities-for-patients-with-inflam-185195d387fcad30Pharma Surgeen2026-07-08T00:00:00.000ZNCT06424769: Improving Outcomes and Reducing Disparities for Patients With Inflammatory Bowel Disease Through Epidemiology and Enhanced Disease Managementhttps://www.pharmaradar360.com/article/nct05564390-myelomatch-a-screening-study-to-assign-people-with-myeloid-cancer-to-24330c5ca77ac0cbPharma Surgeen2026-07-08T00:00:00.000ZNCT05564390: MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)https://www.pharmaradar360.com/article/nct05221502-safety-and-efficacy-evaluation-of-4-month-regimen-of-opc-167832-dela-07012300f78717aaPharma Surgeen2026-07-08T00:00:00.000ZNCT05221502: Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TBhttps://www.pharmaradar360.com/article/nct05142592-phase1-2a-study-for-ipg7236-in-patients-with-advanced-solid-tumors-01c98a95c59f7f14Pharma Surgeen2026-07-08T00:00:00.000ZNCT05142592: Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumorshttps://www.pharmaradar360.com/article/nct05038735-study-to-assess-the-efficacy-and-safety-of-alpelisib-plus-fulvestran-4916c7522ce2f48fPharma Surgeen2026-07-08T00:00:00.000ZNCT05038735: Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.https://www.pharmaradar360.com/article/nct04567420-dna-guided-second-line-adjuvant-therapy-for-high-residual-risk-estro-6a78334fdfaf8069Pharma Surgeen2026-07-08T00:00:00.000ZNCT04567420: DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)https://www.pharmaradar360.com/article/nct04499534-brca1-2-flu-vaccine-8c30beec294491bePharma Surgeen2026-07-08T00:00:00.000ZNCT04499534: BRCA1/2 Flu Vaccinehttps://www.pharmaradar360.com/article/nct04315948-trial-of-treatments-for-covid-19-in-hospitalized-adults-ffec03e02a02a8e6Pharma Surgeen2026-07-08T00:00:00.000ZNCT04315948: Trial of Treatments for COVID-19 in Hospitalized Adultshttps://www.pharmaradar360.com/article/nct04231760-the-effect-of-inhaled-nitric-oxide-on-pulmonary-gas-exchange-in-copd-5b2c213e528c6f00Pharma Surgeen2026-07-08T00:00:00.000ZNCT04231760: The Effect of Inhaled Nitric Oxide on Pulmonary Gas-exchange in COPDhttps://www.pharmaradar360.com/article/nct04015128-a-post-market-clinical-evaluation-of-the-treatment-of-femur-fracture-07816b2d090797a9Pharma Surgeen2026-07-08T00:00:00.000ZNCT04015128: A Post-Market Clinical Evaluation of the Treatment of Femur Fractures With the Femoral Nail GThttps://www.pharmaradar360.com/article/nct03366116-5-aza-4-thio-2-deoxycytidine-aza-tdc-in-people-with-advanced-solid-t-ea4a44cd5ee58dc3Pharma Surgeen2026-07-08T00:00:00.000ZNCT03366116: 5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumorshttps://www.pharmaradar360.com/article/nct03269669-obinutuzumab-with-or-without-umbralisib-lenalidomide-or-combination-251ca73923692b8aPharma Surgeen2026-07-08T00:00:00.000ZNCT03269669: Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphomahttps://www.pharmaradar360.com/article/nct03000244-long-term-follow-up-of-patients-undergoing-hematopoietic-stem-cell-t-17c3ccd3bbfd7d88Pharma Surgeen2026-07-08T00:00:00.000ZNCT03000244: Long-Term Follow up of Patients Undergoing Hematopoietic Stem Cell Transplantation, Cellular Therapy, or Gene Therapyhttps://www.pharmaradar360.com/article/nct02432378-intensive-locoregional-chemoimmunotherapy-for-recurrent-ovarian-canc-69b883b376b294d6Pharma Surgeen2026-07-08T00:00:00.000ZNCT02432378: Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccineshttps://www.pharmaradar360.com/article/nct02154022-collection-of-pharmacokinetic-samples-from-people-with-unanticipated-b606aca2c587c291Pharma Surgeen2026-07-08T00:00:00.000ZNCT02154022: Collection of Pharmacokinetic Samples From People With Unanticipated Response, Significant Toxicity or Concern of Future Toxicityhttps://www.pharmaradar360.com/article/nct01810913-testing-docetaxel-cetuximab-or-the-addition-of-an-immunotherapy-drug-c7f9461417adbdd6Pharma Surgeen2026-07-08T00:00:00.000ZNCT01810913: Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancerhttps://www.pharmaradar360.com/article/nct01582204-evaluate-the-utility-of-124i-cg250-for-the-early-detection-of-respon-f9fe7fd31a1a1c70Pharma Surgeen2026-07-08T00:00:00.000ZNCT01582204: Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinomahttps://www.pharmaradar360.com/article/nct01498263-inherited-diseases-caregiving-and-social-networks-516e94c56e9b605fPharma Surgeen2026-07-08T00:00:00.000ZNCT01498263: Inherited Diseases, Caregiving, and Social Networkshttps://www.pharmaradar360.com/article/nct01352962-gemcitabine-carboplatin-and-lenalidomide-for-treatment-of-advanced-m-95b02a029d39e77dPharma Surgeen2026-07-08T00:00:00.000ZNCT01352962: Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumorshttps://www.pharmaradar360.com/article/nct01087333-collection-of-human-samples-to-study-hairy-cell-and-other-leukemias-e94ed75c99356c21Pharma Surgeen2026-07-08T00:00:00.000ZNCT01087333: Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatmenthttps://www.pharmaradar360.com/article/nct00923065-data-collection-clinical-care-and-interventions-in-ccr-nci-1ee2f0b3238458f3Pharma Surgeen2026-07-08T00:00:00.000ZNCT00923065: Data Collection, Clinical Care and Interventions in CCR, NCIhttps://www.pharmaradar360.com/article/nct00001987-genetic-studies-of-insulin-and-diabetes-839bb8e7d30d357aPharma Surgeen2026-07-08T00:00:00.000ZNCT00001987: Genetic Studies of Insulin and Diabeteshttps://www.pharmaradar360.com/article/medipost-starts-us-phase-3-trial-of-cartistem-to-expand-from-korea-chosunbiz-06da76e67cb13a3cPharma Surgeen2026-07-07T23:54:00.000ZMedipost starts US phase 3 trial of Cartistem to expand from Korea - CHOSUNBIZhttps://www.pharmaradar360.com/article/10-year-capital-plan-to-rebuild-nhs-and-bring-care-closer-to-home-e41690781bc7de8bPharma Surgeen2026-07-07T23:05:00.000Z10 Year Capital Plan to rebuild NHS and bring care closer to homehttps://www.pharmaradar360.com/article/nextgen-vc-podcast-why-the-future-of-biotech-starts-with-the-brain-f52960dd9f0c3e44Pharma Surgeen2026-07-07T22:31:03.000ZNextGen VC Podcast – Why the Future of Biotech Starts with the Brainhttps://www.pharmaradar360.com/article/cmps-stock-clocks-muted-gains-but-analysts-back-psychedelic-drug-s-durability-ah-e2f912a2cb1e14dePharma Surgeen2026-07-07T22:13:06.000ZCMPS Stock Clocks Muted Gains But Analysts Back Psychedelic Drug’s Durability Ahead Of FDA Filinghttps://www.pharmaradar360.com/article/podcast-servier-describes-its-m-a-and-manufacturing-strategy-amidst-deal-making-0cbe957599ce520cPharma Surgeen2026-07-07T21:56:15.000ZPodcast: Servier describes its M&A and manufacturing strategy amidst deal-making drivehttps://www.pharmaradar360.com/article/june-6-2026-judge-blocks-colorado-price-cap-on-enbrel-33e0da6279a0c4d3Pharma Surgeen2026-07-07T21:26:28.000ZJune 6, 2026: Judge blocks Colorado price cap on Enbrelhttps://www.pharmaradar360.com/article/panel-reviews-food-adulteration-cases-406e980fb606225ePharma Surgeen2026-07-07T20:57:57.000ZPanel reviews food adulteration caseshttps://www.pharmaradar360.com/article/first-in-class-drug-approved-for-iga-nephropathy-a36d8e95ed297e40Pharma Surgeen2026-07-07T20:52:59.000ZFirst-in-Class Drug Approved for IgA Nephropathyhttps://www.pharmaradar360.com/article/3-reasons-to-buy-novo-nordisk-stock-6a25836f53ed473fPharma Surgeen2026-07-07T20:36:47.000Z3 Reasons to Buy Novo Nordisk Stockhttps://www.pharmaradar360.com/article/industry-groups-press-fda-for-transparency-next-steps-for-cnpv-program-4fc0d261d56b9066Pharma Surgeen2026-07-07T20:19:00.000ZIndustry groups press FDA for transparency, next steps for CNPV programhttps://www.pharmaradar360.com/article/assembly-panel-reviews-food-adulteration-cases-seeks-stricter-enforcement-7579924c485c27b6Pharma Surgeen2026-07-07T20:04:25.000ZAssembly panel reviews food adulteration cases, seeks stricter enforcementhttps://www.pharmaradar360.com/article/obesity-biotech-kalohexis-confidentially-files-to-go-public-in-us-e785e6640d67808bPharma Surgeen2026-07-07T19:59:53.000ZObesity biotech Kalohexis confidentially files to go public in UShttps://www.pharmaradar360.com/article/coregen-clears-fda-hurdle-to-start-clinical-trials-for-cancer-therapy-this-fall-b268bd4cdf6334ffPharma Surgeen2026-07-07T19:55:00.000ZCoRegen clears FDA hurdle to start clinical trials for cancer therapy this fallhttps://www.pharmaradar360.com/article/the-changing-reality-of-pharmaceutical-commercialization-pharmexec-4fe54bfc12361d4ePharma Surgeen2026-07-07T19:25:29.000ZThe Changing Reality of Pharmaceutical Commercialization | PharmExechttps://www.pharmaradar360.com/article/this-space-bound-biotech-startup-thinks-it-can-cure-cognitive-decline-and-it-jus-0cb529ccd1063bb1Pharma Surgeen2026-07-07T19:22:36.000ZThis Space-Bound Biotech Startup Thinks It Can Cure Cognitive Decline—and It Just Launched a Historic Experimenthttps://www.pharmaradar360.com/article/bedford-approves-tax-incentive-to-bring-300-plus-pharmaceutical-jobs-to-city-e0dd926cef835edePharma Surgeen2026-07-07T19:18:00.000ZBedford approves tax incentive to bring 300-plus pharmaceutical jobs to cityhttps://www.pharmaradar360.com/article/cose-dean-carmen-domingo-honored-for-fostering-next-generation-of-biotech-talent-010ad06419846903Pharma Surgeen2026-07-07T18:56:07.000ZCoSE Dean Carmen Domingo honored for fostering next generation of biotech talenthttps://www.pharmaradar360.com/article/this-biotech-stock-is-soaring-99-after-vertex-agrees-to-takeover-deal-f2b00cb4fc552de5Pharma Surgeen2026-07-07T18:41:00.000ZThis Biotech Stock Is Soaring 99% After Vertex Agrees to Takeover Dealhttps://www.pharmaradar360.com/article/biotech-and-biomed-engineering-grad-and-certificate-programs-to-debut-at-auburn-a7b6667639a44061Pharma Surgeen2026-07-07T18:00:24.000ZBiotech and Biomed Engineering Grad and Certificate Programs to Debut at Auburnhttps://www.pharmaradar360.com/article/axsome-therapeutics-doses-first-pediatric-patient-in-phase-3-adhd-study-c018ab6b063d9acdPharma Surgeen2026-07-07T17:41:00.000ZAxsome Therapeutics doses first pediatric patient in Phase 3 ADHD studyhttps://www.pharmaradar360.com/article/dea-scientist-testifies-against-dea-s-own-rescheduling-posture-in-court-238ba9f6d7a592bePharma Surgeen2026-07-07T17:35:00.000ZDEA Scientist Testifies Against DEA's Own Rescheduling Posture In Courthttps://www.pharmaradar360.com/article/online-glp-1-prescribing-lacks-adequate-safety-oversight-a219cf1c456f91eaPharma Surgeen2026-07-07T16:53:22.000ZOnline GLP-1 Prescribing Lacks Adequate Safety, Oversighthttps://www.pharmaradar360.com/article/merck-kgaa-backed-cyllene-therapeutics-secures-33m-for-gene-therapy-pipeline-fe3b4765de0b2965Pharma Surgeen2026-07-07T16:35:50.000ZMerck KGaA-backed Cyllene Therapeutics secures €33m for gene therapy pipelinehttps://www.pharmaradar360.com/article/sls-stock-sellas-investors-look-for-more-after-542-surge-e44ea3f5331d8efaPharma Surgeen2026-07-07T16:32:12.000ZSLS Stock: SELLAS Investors Look For More After 542% Surgehttps://www.pharmaradar360.com/article/jim-cramer-calls-biotech-the-hottest-group-in-the-market-as-he-predicts-deals-ar-b7734cea981d3088Pharma Surgeen2026-07-07T16:30:17.000ZJim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”https://www.pharmaradar360.com/article/jim-cramer-calls-biotech-the-hottest-group-in-the-market-as-he-predicts-deals-ar-bb158b1232959531Pharma Surgeen2026-07-07T16:30:17.000ZJim Cramer Calls Biotech "The Hottest Group in the Market" as He Predicts "Deals Are Going to Be Flooding the Market"https://www.pharmaradar360.com/article/fda-approves-vera-s-dual-target-trutakna-setting-up-igan-market-battle-with-nova-d2af769a83af6343Pharma Surgeen2026-07-07T16:23:07.000ZFDA approves Vera’s dual-target Trutakna, setting up IgAN market battle with Novartis, Otsukahttps://www.pharmaradar360.com/article/study-identifies-tiered-manufacturing-across-global-pharmaceutical-markets-as-po-b4b47357fb8fa145Pharma Surgeen2026-07-07T16:09:04.000ZStudy Identifies “Tiered Manufacturing” Across Global Pharmaceutical Markets as Potential Determinant of Healthhttps://www.pharmaradar360.com/article/fda-advisory-panel-to-assess-peptide-bulk-drug-substances-from-obesity-to-opioid-5c21d5c320866f96Pharma Surgeen2026-07-07T16:08:22.000ZFDA Advisory Panel to Assess Peptide Bulk Drug Substances from Obesity to Opioidhttps://www.pharmaradar360.com/article/this-small-cap-biotech-is-turning-heads-on-wall-street-52783d3ebae9a9afPharma Surgeen2026-07-07T16:05:00.000ZThis Small-Cap Biotech Is Turning Heads on Wall Streethttps://www.pharmaradar360.com/article/kailera-says-obesity-pill-succeeds-in-late-stage-trial-in-china-f631dadf9197a253Pharma Surgeen2026-07-07T16:03:02.000ZKailera says obesity pill succeeds in late-stage trial in Chinahttps://www.pharmaradar360.com/article/fda-s-regulatory-outlook-897a255287271b38Pharma Surgeen2026-07-07T16:00:00.000ZFDA’s regulatory outlookhttps://www.pharmaradar360.com/article/biotech-supply-chain-market-size-share-growth-report-2034-0bf1acaaa5e8abc0Pharma Surgeen2026-07-07T15:41:40.000ZBiotech Supply Chain Market Size, Share | Growth Report [2034]https://www.pharmaradar360.com/article/novartis-to-acquire-adc-biotech-myricx-bio-for-1-5bn-56b40655fcd95954Pharma Surgeen2026-07-07T15:41:30.000ZNovartis to acquire ADC biotech Myricx Bio for $1.5bnhttps://www.pharmaradar360.com/article/veraxa-biotech-nasdaq-vrxa-shareholders-should-watch-novartis-latest-1-5b-adc-ac-7536759cd5510347Pharma Surgeen2026-07-07T15:35:31.000ZVERAXA Biotech (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5B ADC Acquisitionhttps://www.pharmaradar360.com/article/astrazeneca-developing-pp-blister-packaging-for-future-drugs-d700989ebf81edf4Pharma Surgeen2026-07-07T15:26:00.000ZAstraZeneca developing PP blister packaging for future drugshttps://www.pharmaradar360.com/article/cordis-project-engineered-cartilage-from-nose-for-the-treatment-of-osteoarthriti-382e41fbb850d474Pharma Surgeen2026-07-07T15:21:15.000ZCORDIS project: ENgineered CArtilage from Nose for the Treatment of Osteoarthritis (ENCANTO)https://www.pharmaradar360.com/article/compass-says-depression-drug-has-long-lasting-benefits-2047ae6c03ce0bccPharma Surgeen2026-07-07T15:06:16.000ZCompass says depression drug has long-lasting benefitshttps://www.pharmaradar360.com/article/peptide-exceptionalism-is-a-dangerous-fda-loophole-demand-evidence-not-hype-919d4a33842b47c2Pharma Surgeen2026-07-07T15:00:00.000ZPeptide exceptionalism is a dangerous FDA loophole. Demand evidence, not hypehttps://www.pharmaradar360.com/article/boehringer-bags-pvt-s-viral-vector-platform-for-cancer-vaccine-r-d-ad7dd9fe82d08aadPharma Surgeen2026-07-07T14:35:39.000ZBoehringer bags PVT’s viral vector platform for cancer vaccine R&D